CBAY - CymaBay announces result from Phase 2 trial of primary biliary cholangitis therapy

CymaBay Therapeutics (NASDAQ:CBAY) announced results from the Phase 2, 52-week study of Seladelpar in patients with primary biliary cholangitis (PBC). The company said the mid-stage study examined the efficacy and safety of seladelpar in adults with PBC who were receiving or intolerant to first-line therapy with ursodeoxycholic acid.  The primary efficacy analysis found that seladelpar treatment provided 26%, 33%, and 41% reductions for the 2 mg, 5 mg and 10 mg doses, respectively, in the alkaline phosphatase level at week 8. The company said responses were maintained or improved at Week 52. Primary biliary cholangitis is a chronic disease in which the bile ducts in your liver are slowly destroyed.

For further details see:

CymaBay announces result from Phase 2 trial of primary biliary cholangitis therapy